Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
Purpose: after cisplatin-based neoadjuvant chemotherapy (NAC), 60% of patients with muscle-invasive bladder cancer (MIBC) still have residual invasive disease at radical cystectomy. The NAC-induced biological alterations in these cisplatin-resistant tumors remain largely unstudied.
Experimental design: radical cystectomy samples were available for gene expression analysis from 133 patients with residual invasive disease after cisplatin-based NAC, of whom 116 had matched pre-NAC samples. Unsupervised consensus clustering (CC) was performed and the consensus clusters were investigated for their biological and clinical characteristics. Hematoxylin & Eosin and IHC on tissue microarrays were used to confirm tissue sampling and gene expression analysis.
Results: established molecular subtyping models proved to be inconsistent in their classification of the post-NAC samples. Unsupervised CC revealed four distinct consensus clusters. The CC1-Basal and CC2-Luminal subtypes expressed genes consistent with a basal and a luminal phenotype, respectively, and were similar to the corresponding established pretreatment molecular subtypes. The CC3-Immune subtype had the highest immune activity, including T-cell infiltration and checkpoint molecule expression, but lacked both basal and luminal markers. The CC4-Scar–like subtype expressed genes associated with wound healing/scarring, although the proportion of tumor cell content in this subtype did not differ from the other subtypes. Patients with CC4-Scar–like tumors had the most favorable prognosis.
Conclusions: this study expands our knowledge on MIBC not responding to cisplatin by suggesting molecular subtypes to understand the biology of these tumors. Although these molecular subtypes imply consequences for adjuvant treatments, this ultimately needs to be tested in clinical trials.
Journal Article
5082-5093
Seiler, Roland
dea9a9c3-49d9-438c-b611-f558058de347
Gibb, Ewan A.
0f360aa2-3f90-4f79-9746-00ed593e521e
Wang, Natalie Q.
5502fb67-9ce5-48ca-9dd1-0f8eaf6b1a86
Oo, Htoo Zarni
44c067f9-127a-4113-94fe-44453c4b0675
Lam, Hung Ming
1fdf7434-9b2f-471a-a71b-8b1c8136f497
van Kessel, Kim E.
413915e5-addd-4243-be0c-b825dde29e18
Voskuilen, Charlotte S.
d5400a01-016c-4f18-ac84-d0183694c2a1
Winters, Brian
28cc30be-6e7f-4416-b154-1f1f9a9ffc7b
Erho, Nicholas
07148ea7-7bb8-4924-bb72-efa221ff5440
Takhar, Mandeep M.
a685bc54-d6fa-4450-95d2-0064d5a53e83
Douglas, James
113c1170-c37f-46bc-9d1c-38843b080abe
Vakar-Lopez, Funda
8820be67-2007-4e45-8107-6b80e2445783
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
van Rhijn, Bas W.G.
6b157295-1b24-4e59-8d4c-c02b4912311d
Fransen van de Putte, Elisabeth E.
8dcaa12f-e0fb-4da7-935d-cb8c91f4cb65
Zwarthoff, Ellen C.
97a3c8d2-f310-4054-9662-57372d240838
Thalmann, George N.
bc21cffd-7bdb-4469-a208-28219f3de5d4
Davicioni, Elai
8d0ac603-abf4-4d0e-894e-975a2edb318b
Boormans, Joost L.
4f22065e-656b-4d5e-8e5f-9b5812158c51
Dall'Era, Marc
5236d9b8-175e-4fe0-abea-f24bc77030c5
van der Heijden, Michiel S.
70ee9b04-1371-4eb8-8f9e-4f24b4c9101d
Wright, Jonathan L.
2b5a4f14-69ae-4a14-b073-399cd499e1ca
Black, Peter C.
16f69c4b-5aa2-43b8-b179-a5ca2856bb69
15 August 2019
Seiler, Roland
dea9a9c3-49d9-438c-b611-f558058de347
Gibb, Ewan A.
0f360aa2-3f90-4f79-9746-00ed593e521e
Wang, Natalie Q.
5502fb67-9ce5-48ca-9dd1-0f8eaf6b1a86
Oo, Htoo Zarni
44c067f9-127a-4113-94fe-44453c4b0675
Lam, Hung Ming
1fdf7434-9b2f-471a-a71b-8b1c8136f497
van Kessel, Kim E.
413915e5-addd-4243-be0c-b825dde29e18
Voskuilen, Charlotte S.
d5400a01-016c-4f18-ac84-d0183694c2a1
Winters, Brian
28cc30be-6e7f-4416-b154-1f1f9a9ffc7b
Erho, Nicholas
07148ea7-7bb8-4924-bb72-efa221ff5440
Takhar, Mandeep M.
a685bc54-d6fa-4450-95d2-0064d5a53e83
Douglas, James
113c1170-c37f-46bc-9d1c-38843b080abe
Vakar-Lopez, Funda
8820be67-2007-4e45-8107-6b80e2445783
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
van Rhijn, Bas W.G.
6b157295-1b24-4e59-8d4c-c02b4912311d
Fransen van de Putte, Elisabeth E.
8dcaa12f-e0fb-4da7-935d-cb8c91f4cb65
Zwarthoff, Ellen C.
97a3c8d2-f310-4054-9662-57372d240838
Thalmann, George N.
bc21cffd-7bdb-4469-a208-28219f3de5d4
Davicioni, Elai
8d0ac603-abf4-4d0e-894e-975a2edb318b
Boormans, Joost L.
4f22065e-656b-4d5e-8e5f-9b5812158c51
Dall'Era, Marc
5236d9b8-175e-4fe0-abea-f24bc77030c5
van der Heijden, Michiel S.
70ee9b04-1371-4eb8-8f9e-4f24b4c9101d
Wright, Jonathan L.
2b5a4f14-69ae-4a14-b073-399cd499e1ca
Black, Peter C.
16f69c4b-5aa2-43b8-b179-a5ca2856bb69
Seiler, Roland, Gibb, Ewan A., Wang, Natalie Q., Oo, Htoo Zarni, Lam, Hung Ming, van Kessel, Kim E., Voskuilen, Charlotte S., Winters, Brian, Erho, Nicholas, Takhar, Mandeep M., Douglas, James, Vakar-Lopez, Funda, Crabb, Simon J., van Rhijn, Bas W.G., Fransen van de Putte, Elisabeth E., Zwarthoff, Ellen C., Thalmann, George N., Davicioni, Elai, Boormans, Joost L., Dall'Era, Marc, van der Heijden, Michiel S., Wright, Jonathan L. and Black, Peter C.
(2019)
Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Clinical Cancer Research, 25 (16), .
(doi:10.1158/1078-0432.CCR-18-1106).
Abstract
Purpose: after cisplatin-based neoadjuvant chemotherapy (NAC), 60% of patients with muscle-invasive bladder cancer (MIBC) still have residual invasive disease at radical cystectomy. The NAC-induced biological alterations in these cisplatin-resistant tumors remain largely unstudied.
Experimental design: radical cystectomy samples were available for gene expression analysis from 133 patients with residual invasive disease after cisplatin-based NAC, of whom 116 had matched pre-NAC samples. Unsupervised consensus clustering (CC) was performed and the consensus clusters were investigated for their biological and clinical characteristics. Hematoxylin & Eosin and IHC on tissue microarrays were used to confirm tissue sampling and gene expression analysis.
Results: established molecular subtyping models proved to be inconsistent in their classification of the post-NAC samples. Unsupervised CC revealed four distinct consensus clusters. The CC1-Basal and CC2-Luminal subtypes expressed genes consistent with a basal and a luminal phenotype, respectively, and were similar to the corresponding established pretreatment molecular subtypes. The CC3-Immune subtype had the highest immune activity, including T-cell infiltration and checkpoint molecule expression, but lacked both basal and luminal markers. The CC4-Scar–like subtype expressed genes associated with wound healing/scarring, although the proportion of tumor cell content in this subtype did not differ from the other subtypes. Patients with CC4-Scar–like tumors had the most favorable prognosis.
Conclusions: this study expands our knowledge on MIBC not responding to cisplatin by suggesting molecular subtypes to understand the biology of these tumors. Although these molecular subtypes imply consequences for adjuvant treatments, this ultimately needs to be tested in clinical trials.
Text
Seiler divergent biological reponse to NAC
- Accepted Manuscript
More information
Accepted/In Press date: 11 September 2018
e-pub ahead of print date: 17 September 2018
Published date: 15 August 2019
Keywords:
Journal Article
Identifiers
Local EPrints ID: 423818
URI: http://eprints.soton.ac.uk/id/eprint/423818
ISSN: 1078-0432
PURE UUID: e74700ad-609e-46b1-9495-40d7577d5f11
Catalogue record
Date deposited: 02 Oct 2018 16:30
Last modified: 25 Jul 2024 04:01
Export record
Altmetrics
Contributors
Author:
Roland Seiler
Author:
Ewan A. Gibb
Author:
Natalie Q. Wang
Author:
Htoo Zarni Oo
Author:
Hung Ming Lam
Author:
Kim E. van Kessel
Author:
Charlotte S. Voskuilen
Author:
Brian Winters
Author:
Nicholas Erho
Author:
Mandeep M. Takhar
Author:
James Douglas
Author:
Funda Vakar-Lopez
Author:
Bas W.G. van Rhijn
Author:
Elisabeth E. Fransen van de Putte
Author:
Ellen C. Zwarthoff
Author:
George N. Thalmann
Author:
Elai Davicioni
Author:
Joost L. Boormans
Author:
Marc Dall'Era
Author:
Michiel S. van der Heijden
Author:
Jonathan L. Wright
Author:
Peter C. Black
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
